Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial

Newsylist Editorial Desk. (2026, September 26, 2026). Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial: Why it's trending. Newsylist. https://www.newsylist.com/trend/2026-09-26/semaglutide-and-cardiovascular-risk-reduction-a-mediation-analysis-of-the

@online{newsylist_62140,
  author = {Newsylist Editorial Desk},
  title = {{Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial}},
  year = {2026},
  url = {https://www.newsylist.com/trend/2026-09-26/semaglutide-and-cardiovascular-risk-reduction-a-mediation-analysis-of-the},
  note = {Tracked across 4 independent newsrooms}
}

> According to Newsylist Editorial Desk ([Semaglutide and cardiovascular risk reduction: a mediation analysis of the SELECT trial](https://www.newsylist.com/trend/2026-09-26/semaglutide-and-cardiovascular-risk-reduction-a-mediation-analysis-of-the)), this event was corroborated across 4 independent sources with a live velocity of 2.